OVARIAN MUCINOUS ADENOCARCINOMA
Clinical trials for OVARIAN MUCINOUS ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new OVARIAN MUCINOUS ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for OVARIAN MUCINOUS ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Major trial aims to tame dozens of rare, neglected cancers with immune power combo
Disease control OngoingThis large national trial is testing whether a combination of two immunotherapy drugs (nivolumab and ipilimumab) can help control over 50 different types of rare cancers that have few or no standard treatment options. It enrolled over 800 adults whose rare cancers had progressed …
Matched conditions: OVARIAN MUCINOUS ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Major trial tests if weekly chemo beats standard schedule for tough cancers
Disease control OngoingThis large, Phase 3 trial aimed to find out if giving a key chemotherapy drug (paclitaxel) once a week is better than giving it once every three weeks for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer. All patients also received another standard che…
Matched conditions: OVARIAN MUCINOUS ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Scientists weaponize measles virus to fight ovarian cancer
Disease control OngoingThis study is testing a new treatment for ovarian, fallopian tube, or primary peritoneal cancer that has come back after standard therapy. Doctors are using a specially engineered measles virus, which is carried directly to the cancer by the patient's own fat-derived stem cells, …
Matched conditions: OVARIAN MUCINOUS ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC